Roivant Sciences Ltd. - Common Shares (ROIV)
ROIV moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How ROIV actually reacts to news — the realized, point-in-time move the market made, measured across 579 labeled events over the last three years with zero look-ahead.
ROIV’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 49% | 577 |
| 30-min | 0.00% | 50% | 577 |
| 60-min | +0.05% | 52% | 577 |
| to close | 0.00% | 50% | 576 |
| Middle 50% of ROIV reactions | -0.75% to +0.94% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 579 |
Half of all Roivant Sciences Ltd. - Common Shares news events land between -0.75% and +0.94% at 30 minutes.
Reaction stats as of 2026-08-31. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ROIV reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 18 | +0.12% | 50% | +1.21% |
| Rating reiterations | 95 | +0.10% | 58% | -0.16% |
| Price-target raises | 17 | +0.07% | 59% | +0.31% |
Last 3 years, pulled 2026-08-31. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how ROIV ranks against every other measured name →
That’s how ROIV usually reacts — get an email when it moves on news →Email me when ROIV moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ROIV's baseline. Nothing else.
Recent ROIV events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Roivant Sciences Ltd. For: Aug 28 | SEC filing · Form 8-K | SEC EDGAR | +0.72% | -0.20% | |
| Form 8-K Roivant Sciences Ltd. For: Aug 27 | SEC filing · Form 8-K | SEC EDGAR | -0.78% | -6.21% | |
| Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. | Press release | GlobeNewswire | -0.66% | -0.46% | |
| Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. | Press release | GlobeNewswire | -0.62% | -0.15% | |
| JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis | Press release | GlobeNewswire | -0.03% | +0.66% | |
| Form 10-Q Roivant Sciences Ltd. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.23% | +6.07% | |
| Form 8-K Roivant Sciences Ltd. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +4.23% | +6.07% | |
| Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS) | Press release | GlobeNewswire | +4.23% | +6.07% | |
| Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update | Press release | GlobeNewswire | +4.23% | +6.07% | |
| Form ARS Roivant Sciences Ltd. For: Mar 31 | SEC filing · Form ARS | SEC EDGAR | +0.78% | -3.01% | |
| Form DEF 14A Roivant Sciences Ltd. For: Sep 16 | SEC filing · Form DEF | SEC EDGAR | +0.78% | -3.01% | |
| Form DEFA14A Roivant Sciences Ltd. | SEC filing · Form DEFA14A | SEC EDGAR | +0.78% | -3.01% | |
| Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 | Press release | GlobeNewswire | -0.41% | -0.62% | |
| Form 10-K Roivant Sciences Ltd. For: Mar 31 | SEC filing · Form 10-K | SEC EDGAR | +4.09% | +9.49% | |
| Form 8-K Roivant Sciences Ltd. For: May 20 | SEC filing · Form 8-K | SEC EDGAR | +4.09% | +9.49% | |
| Form S-8 Roivant Sciences Ltd. | SEC filing · Form S-8 | SEC EDGAR | +0.42% | -4.01% | |
| Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update | Press release | GlobeNewswire | +4.09% | +9.49% | |
| Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026 | Press release | GlobeNewswire | -0.69% | +1.31% | |
| Form 8-K Roivant Sciences Ltd. For: Apr 02 | SEC filing · Form 8-K | SEC EDGAR | +1.52% | +5.12% | |
| Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) | Press release | GlobeNewswire | +1.52% | +5.12% | |
| Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Press release | GlobeNewswire | +1.52% | +5.12% | |
| New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis | Press release | GlobeNewswire | -1.06% | -1.38% | |
| Form 8-K/A Roivant Sciences Ltd. For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | +0.60% | +0.83% | |
| Form 8-K Roivant Sciences Ltd. For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | -1.02% | +1.90% | |
| Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis | Press release | GlobeNewswire | -1.02% | +1.90% | |
| Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna | Press release | GlobeNewswire | +2.34% | +3.80% | |
| Form 10-Q Roivant Sciences Ltd. For: Dec 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.53% | +5.39% | |
| Form 8-K Roivant Sciences Ltd. For: Feb 06 | SEC filing · Form 8-K | SEC EDGAR | -0.53% | +5.39% | |
| Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) | Press release | GlobeNewswire | -0.53% | +5.39% | |
| Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) | Press release | GlobeNewswire | -0.53% | +5.39% | |
| Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 | Press release | GlobeNewswire | -0.53% | +5.39% | |
| Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 | Press release | GlobeNewswire | -0.33% | +1.11% | |
| Form 8-K Roivant Sciences Ltd. For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | +1.43% | +5.38% | |
| Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day | Press release | GlobeNewswire | +1.43% | +5.38% | |
| Form 10-Q Roivant Sciences Ltd. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.65% | +5.01% | |
| Form 8-K Roivant Sciences Ltd. For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | -0.65% | +5.01% | |
| Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update | Press release | GlobeNewswire | -0.65% | +5.01% | |
| Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 | Press release | GlobeNewswire | -0.21% | -2.13% | |
| Form S-3ASR Roivant Sciences Ltd. | SEC filing · Form S-3ASR | SEC EDGAR | +0.33% | -0.97% | |
| Form 8-K Roivant Sciences Ltd. For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | +0.38% | -3.54% | |
| Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) | Press release | GlobeNewswire | +0.38% | -3.54% | |
| Form 8-K Roivant Sciences Ltd. For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +0.07% | -2.22% | |
| Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List | Press release | GlobeNewswire | +0.07% | -2.22% | |
| Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) | Press release | GlobeNewswire | +1.67% | -0.08% | |
| Form 8-K Roivant Sciences Ltd. For: Sep 03 | SEC filing · Form 8-K | SEC EDGAR | -0.04% | -0.16% | |
| Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | Press release | GlobeNewswire | +0.56% | +1.17% | |
| Form 10-Q Roivant Sciences Ltd. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.84% | +2.48% | |
| Form 8-K Roivant Sciences Ltd. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +2.84% | +2.48% | |
| Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update | Press release | GlobeNewswire | +2.84% | +2.48% | |
| Form ARS Roivant Sciences Ltd. For: Mar 31 | SEC filing · Form ARS | SEC EDGAR | -0.09% | -0.35% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ROIV section they belong to.
Where else ROIV is measured.
ROIV earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Roivant Sciences Ltd. - Common Shares's median reaction calculated?
Every labeled ROIV news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 579 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of ROIV's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-31.
Does ROIV's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.